Athersys Treatment for Stem Cell Transplant Complication Gets Orphan Status in ... Wall Street Journal Athersys Inc. (ATHX) said its therapy to prevent a type of complication in patients receiving stem cell transplants was granted orphan drug status by European regulators. Shares were up 11% at $2.25 in recent premarket trading. The biotechnology ... Athersys: EMA issues positive opinion on MultiStem Cell therapy |
